Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032
Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032

Dr. Patrick Soon-Shiong, Executive Chairman of ImmunityBio, provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept (Anktiva) for NMIBC presented at the AUA 2024 Annual Meeting.

Dr. Soon-Shiong shares how the IL-15 agonist agent works, the next line of research for the immunoagent now that the FDA has approved it for BCG-unresponsive patients with NMIBC, and how ImmunityBio is addressing the worldwide BCG shortage.

Advertisement

Latest News

Preoperative Risk Calculator for Evaluating Nephron-Sparing Completion in Kidney Cancer
Preoperative Risk Calculator for Evaluating Nephron-Sparing Completion in Kidney Cancer
Katy MarshallLocalized Renal Cell Carcinoma | May 10, 2024
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Re-treating Locally Recurrent PCa With EBRT Is Feasible
Re-treating Locally Recurrent PCa With EBRT Is Feasible
Emily MenendezLocalized | May 10, 2024
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Carboplatin, PD-1 Inhibitors Preferred Over Cisplatin-Based Regimens for aUC in New Study
Carboplatin, PD-1 Inhibitors Preferred Over Cisplatin-Based Regimens for aUC in New Study
Emily MenendezAdvanced Urothelial Carcinoma | May 8, 2024
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
Impact of Cytoreductive Nephrectomy on Survival Benefits for Patients With Metastatic nccRCC
Impact of Cytoreductive Nephrectomy on Survival Benefits for Patients With Metastatic nccRCC
Katy MarshallnccRCC | May 8, 2024
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy
Eric Li, MDProstate Cancer Diagnostics | May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Enzalutamide Plus LuPSMA Improves PFS in mCRPC
Enzalutamide Plus LuPSMA Improves PFS in mCRPC
Emily MenendezCRPC | May 7, 2024
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
Apalutamide Plus ADT May Benefit Patients With High-Risk Localized Prostate Cancer
Apalutamide Plus ADT May Benefit Patients With High-Risk Localized Prostate Cancer
Katy MarshallLocalized | May 7, 2024
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up
Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Risk Score to Identify Optimal Patients for Adjuvant RT After Radical Prostatectomy
Risk Score to Identify Optimal Patients for Adjuvant RT After Radical Prostatectomy
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Patient Selection, Counseling, and Improved Biomarkers, Imaging: Moving Forward From KEYNOTE-564
Patient Selection, Counseling, and Improved Biomarkers, Imaging: Moving Forward From KEYNOTE-564
Sarah Psutka, MD, MScRenal Cell Carcinoma Diagnostics | May 7, 2024
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Characterizing Benefit in Responders in the CheckMate 901 Trial
Characterizing Benefit in Responders in the CheckMate 901 Trial
Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | May 7, 2024
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Fellow at the University of Southern California
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

Expert Interviews

Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRSAUA 2024 | April 30, 2024
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Daniel Spratt, MD – Offering Mentorship, Purpose for Aspiring Radiation Oncologists
Daniel Spratt, MD – Offering Mentorship, Purpose for Aspiring Radiation Oncologists
Daniel Spratt, MDLocalized | April 17, 2024
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Utilizing miRNA as a Liquid Biomarker for Malignancy of Small Testicular Masses
Utilizing miRNA as a Liquid Biomarker for Malignancy of Small Testicular Masses
Julian Chavarriaga, MDTesticular, Penile, and Rare Malignancies | April 12, 2024
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Leonard Gomella, MD, FACS – A Decades-Long Commitment to Advancing Urology
Leonard Gomella, MD, FACS – A Decades-Long Commitment to Advancing Urology
Leonard Gomella, MD, FACSProstate Cancer Diagnostics | April 10, 2024
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Shilpa Gupta, MD – From Fellowship to Leadership in GU Oncology Research
Shilpa Gupta, MD – From Fellowship to Leadership in GU Oncology Research
Shilpa Gupta, MDProstate Cancer | April 5, 2024
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
James Sylora, MD – Bridging Gaps for Focal Therapy in Community Urology
James Sylora, MD – Bridging Gaps for Focal Therapy in Community Urology
James Sylora, MDLocalized | April 3, 2024
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mCSPC
mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 317: AUA 2024 Preview
Episode 317: AUA 2024 Preview
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.
# Posted on May 4, 2024
# Uromigos-Bladder Cancer
Episode 316: APCCC 2024 Summary With Silke Gillessen
Episode 316: APCCC 2024 Summary With Silke Gillessen
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
# Posted on April 30, 2024
# Uromigos-Prostate Cancer
Episode 315: ACCC 2024 - Bone Health, Hot Flashes and Gynecomastia in Prostate Cancer
Episode 315: ACCC 2024 - Bone Health, Hot Flashes and Gynecomastia in Prostate Cancer
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
# Posted on April 30, 2024
# Uromigos-Prostate Cancer

Conference Coverage

Live meeting highlights

Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy
Eric Li, MDProstate Cancer Diagnostics | May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
View More
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
View More
Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
View More
Risk Score to Identify Optimal Patients for Adjuvant RT After Radical Prostatectomy
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Read More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy